Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.

Drug discovery today - 1 Feb 2007

Kooloos Wouter M, de Jong Dirk J, Huizinga Tom W J, Guchelaar Henk-Jan

Abstract excerpt

Etanercept, infliximab and adalimumab have shown clinical benefit in immune-mediated inflammatory diseases; however, the outcome of treatment with these tumour-necrosis factor inhibitors remains insufficient in approximately 40-60% and approximately 25-40% of individuals with rheumatoid arthritis and Crohn's disease, respectively. Moreover, their use is accompanied by adverse events and unintentional immune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antirheumatic Agents

Share to Crohn Disease

Share to Etanercept

Share to Immunoglobulin G

Share to Infliximab

Share to Receptors, Tumor Necrosis Factor

Source

Identifiers

PMID: 17275732
DOI: 10.1016/j.drudis.2006.11.013

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.PMID 17275732Read ↗

Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy.Semantic proximity Read ↗

Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.Semantic proximity Read ↗

Pharmacogenetics of Inflammatory Bowel DiseaseSemantic proximity Read ↗

Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?Semantic proximity Read ↗

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Semantic proximity Read ↗

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?Semantic proximity Read ↗

Pharmacogenetics in treatment of rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.Semantic proximity Read ↗

Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of inflammatory bowel disease.Semantic proximity Read ↗

Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.